FundComb

Investment and M&A transaction comps

Biotech & Pharma Investment & M&A Transaction Comps

Biotech, pharma, therapeutics, platform technology and life-sciences asset transactions. Revenue and EBITDA multiples are shown where meaningful; milestone, royalty, stage and asset-basis notes matter more for many pre-commercial deals.

Consumer CPG Beauty Supplements Food & Beverage Software Healthcare Biotech Industrials
31
Reviewed transactions
16
With price data
4.5x
Median EV or valuation / revenue
13.5x
Median EV or valuation / EBITDA
Year Transactions Priced Median EV or valuation / revenue Median EV or valuation / EBITDA
2026 16 7 6.0x -
2022 3 2 4.4x 17.1x
2021 3 2 - 11.9x

Sortable transaction comps

Biotech transaction table

Filter transactions

Narrow the table without crowding the main view.

Clear all filters

Rows with reported value

5 / 6

Acquisition EV, USD

USD 33B

Investment EV, USD

-

Median EV / revenue

4.6x

Columns

Show columns

Select up to 12 rows across filters and pages, then share or export the set.

6 shown of 31 matching transactions. Click any transaction row for more detail.

Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately.

Select for comparison
Dermira
Control
 2020-01-10 Eli Lilly 1,100 - -
Biotech
Celgene
Control
 2019-01-03 Bristol-Myers Squibb Undisclosed - -
BiotechPharmaLife Sciences
2017-12-26 Mallinckrodt 1,200 4.6x -
Pharma
2015-06-17 Allergan 2,100 - -
BiotechMedical Aesthetics
2007-12-11 Reckitt Benckiser Group plc 2,300 6.4x 30.4x
Consumer HealthPharma
2005-07-01 International Flavors & Fragrances (IFF) 26,200 4.3x 18.9x
Food IngredientsSupplementsLife Sciences
FundComb transaction comps are informational only. Prices are shown as estimated enterprise value where available, with USD used as the default sorting currency; revenue and EBITDA multiples are shown where available. Values may be estimated, rumored, incomplete or derived from public information and should not be relied upon as financial, investment or valuation advice.